Track topics on Twitter Track topics that are important to you
CytoReason, developer of the world's first machine learning platform for human immune system cell-level simulation, today announces publication of a groundbreaking new model for translating data from ...
(CytoReason) CytoReason, developer of the world's first machine learning platform for human immune system cell-level simulation, today announces publication of a groundbreaking new model for translati...
The results, presented at the American Association for Cancer Research Special AI Conference, identifies the potential involvement of adipocytes in nivolumab (anti-PD1) response i...
New findings presented today by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients - those who have al...
New Data Published by Nature Biotechnology Covering 16,000,000 scientific articles, this massive Natural Language Processing (NLP) project quadruples the reference ...
Groundbreaking model translates the results of new mouse experiments into the equivalent human condition, outperforming traditional methods of extrapolation by up to 50%. This cou...
(CytoReason) New data published in Nature Biotech, represents the largest ever analysis of immune cell signaling research, mapping more than 3,000 previously unlisted cellular interactions, and yieldi...
Born out of 10 yearsâ research from Stanford and the Technion, CytoReason is the only AI company to focus entirely on the immune system in developing its proprietary data and...
We have published hundreds of CytoReason news stories on BioPortfolio along with dozens of CytoReason Clinical Trials and PubMed Articles about CytoReason for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CytoReason Companies in our database. You can also find out about relevant CytoReason Drugs and Medications on this site too.